Jennifer J.Chheda Ph.D.

Partner

New York + 1.212.326.3886

Connect:

Share

Dr. Jennifer Chheda has almost 20 years of experience developing, implementing, and managing worldwide patent portfolios covering commercial biologics and pharmaceuticals as well as products in development, including clinical candidates.

Jennifer has been instrumental in the development, implementation, and management of patent portfolios for MedImmune relating to its commercial anti-RSV F antibody; patent portfolios for Icahn School of Medicine at Mount Sinai relating to influenza virus vaccines and chimeric Newcastle Disease Viruses in development; and patent portfolios for AC Immune S.A. and Genentech relating to anti-beta amyloid antibodies, including Genentech's clinical candidate. Jennifer has worked with pioneers developing a universal influenza virus vaccine as well as virus-based cancer therapy. In addition, she was instrumental in developing and managing global patent portfolios for Admune Therapeutics relating to its IL-15/IL-15 receptor alpha clinical trial product, which formed the basis for the acquisition of Admune by Novartis Institutes for BioMedical Research. Furthermore, she has evaluated patent portfolios and prosecuted patent applications relating to, inter alia, enzyme replacement therapy, RNA therapeutics (e.g., miRNA), gene therapy, antibodies, antibody drug conjugates, and cell-based therapies (e.g., CAR-T cells).

Jennifer's experience also includes patentability, invalidity, noninfringement, and freedom-to-operate analyses; conducting due diligences for clients, including potential investors, acquirers, and licensees, such as venture capital firms, biotechnology companies, and pharmaceutical companies; inventorship analysis; and post-grant proceedings, such as inter partes review, interferences, reexaminations, and oppositions.

Jennifer also has experience drafting and negotiating intellectual property agreements, including licensing, sponsored research, and development agreements. In addition, she has patent litigation experience, including drafting expert reports, preparing experts for trial, and drafting legal arguments for briefs.

Experience

  • AbbVie to acquire Mitokinin, Inc.Jones Day is advising AbbVie Inc. in its exclusive right to acquire Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, following completion of IND enabling studies on Mitokinin's lead PINK1 compound.
  • Merck unit files DJ action involving pneumococcal vaccine patentsJones Day is representing Merck Sharp & Dohme Corp. in an action in Delaware district court against Wyeth, LLC seeking declaratory judgment of invalidity and non-infringement of U.S. patent Nos. 8,895,024; 8,808,708 and 9,399,060 relating to a new 15-valent pneumococcal conjugate vaccine, known as V114, for the prevention of invasive pneumococcal disease in adults 18 years of age and older.
  • Shiseido acquires Olivo LaboratoriesJones Day advised Shiseido Americas Corporation, a subsidiary of Shiseido Co., Ltd., a leading global cosmetics company, in connection with the acquisition of substantially all of the assets of Olivo Laboratories, LLC, a startup advancing the dermatological field through proprietary biomaterials technology.
  • Celgene acquires Triphase Accelerator's first compound, MarizomibJones Day advised Celgene Corporation in the acquisition, through an affiliate, of Triphase Accelerator Corporation's assets related to its proteasome inhibitor, marizomib (MRZ), which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
  • REGENXBIO and Biogen enter exclusive license agreement for development of gene therapy treatments for rare genetic vision disordersJones Day advised REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, in connection with an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV® Technology Platform for the treatment of two rare genetic vision disorders.
  • Merial successfully defends patent-ineligibility ruling before Federal CircuitJones Day, on behalf of Merial L.L.C., successfully obtained a precedential opinion from an unanimous panel of the U.S. Court of Appeals for the Federal Circuit on April 8, 2016, affirming a district court judgment that a patent asserted against Merial, as well as numerous other biotechnology and pharmaceuticals companies, is invalid under 35 U.S.C. § 101.
  • Idenix challenges Gilead's patent rights to Sovaldi® (sofosbuvir)Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent interference against Gilead.
  • St. Jude and Juno secure $12.25 million settlement resolving patent dispute with Novartis Pharmaceuticals and University of PennsylvaniaJones Day represented St. Jude Children's Research Hospital ("St. Jude") in enforcing breach of contract claims and defending patent invalidity claims against the University of Pennsylvania ("Penn") and Novartis Pharmaceuticals ("Novartis").
  • Merial wins dismissal of patent claims directed to ineligible subject matterJones Day, with Merial Limited's Global Head of Intellectual Property, Dr. Judy Jarecki-Black, Esq., successfully defended Merial in a patent infringement case brought by Genetic Technologies Limited ("GTG").
  • Jefferies and Piper Jaffray underwrite $60.9 million IPO of Common Stock by Marrone Bio InnovationsJones Day advised Jefferies LLC and Piper Jaffray & Co., as underwriters, in connection with the $60.9 million initial public offering of Common Stock by Marrone Bio Innovations, Inc., a provider of bio-based pest management and plant health products for the agricultural and water treatment markets.
  • Leading U.S. cancer research institute successfully defends antibody patent in EuropeJones Day successfully represented major U.S. cancer research institute in opposition proceedings before the European Patent Office.
  • Jazz Pharmaceuticals acquires EUSA Pharma for $650 millionJones Day acted as IP counsel in advising Jazz Pharmaceuticals, Inc. in connection with the execution of a definitive agreement under which Jazz Pharmaceuticals has agreed to acquire EUSA Pharma for $650 million in cash and a potential $50 million milestone payable in cash based upon Erwinaze™ achieving a specified U.S. net sales target in 2013.
  • Martek Biosciences wins across-the-board victory in biotech dispute before five-judge Federal Circuit panelOn September 3, 2009, a rare five-judge panel of the U.S. Court of Appeals for the Federal Circuit issued an across-the-board appellate victory for Jones Day client Martek Biosciences Corp. in Martek Biosciences Corp. v. Nutrinova, Inc., Nos. 2008-1459 and 2008-1476.
  • King Pharmaceuticals faces Item Development AB in patent interference involving myocardial dysfunctionJones Day provided representation to King Pharmaceuticals, Inc. in a patent interference against Item Development AB before the U.S. Patent and Trademark Office involving methods for detecting the presence and assessing the severity of myocardial dysfunction.
  • MedImmune licenses in IP on antibodies that target IL-5 receptorJones Day represented MedImmune in an exclusive license to BioWa's POTELLIGENT technology platform and related intellectual property directed to antibodies that target the interleukin-5 (IL-5) receptor, including the transfer of Phase I clinical trials for treatment of asthma and other inflammatory diseases.
  • MacroGenics maintains patent portfolio for biologics, immunotherapeutics and cancer targetsJones Day managed the patent portfolio and prosecuted key patents on behalf of MacroGenics, Inc. related to biologics, immunotherapeutics and cancer targets, particularly with respect to antibodies and other molecules that target Fc receptors.
  • Genencor defends against patent infringement claims brought by Novozymes over enzymes used in ethanol fuel productionJones Day represented Genencor in a patent infringement litigation related to alpha amylase enzymes used in the production of fuel ethanol.
    • View All

    January 2019 Alerts

    Secret Sales Are Still Prior Art: U.S. Supreme Court Affirms Helsinn Healthcare

    October 2018 Blogs

    Post-Priority Document Usable As Evidence of POSITA Motivation, PTAB Litigation Blog

    August 2018 Blogs

    Petition For Writ Of Mandamus Not An End Run Around Cuozzo, PTAB Litigation Blog

    July 2018 Blogs

    Federal Circuit Grants Motion Remanding For Consideration Of All Grounds, PTAB Litigation Blog

    February 2018 Blogs

    Patent Prosecutors Beware: Earlier Publication Anticipates Broad Claims of Continuing Application, PTAB Litigation Blog

    November 2017 Commentaries

    Federal Circuit Clarifies Probative Value of Patent Dance Statements

    June 2017 Commentaries

    Supreme Court: Biosimilar Applicants May Provide Commercial Marketing Notice Before FDA Approval

    May 2017 Jones Day Publications

    Supreme Court Hears Oral Arguments in Sandoz Inc. v. Amgen Inc.

    May 2017 Commentaries

    Meet the New Boss, Same as the Old Boss: Federal Circuit Interprets AIA's On-Sale Bar

    March 2017 Blogs

    PTAB Denies Institution of IPR Proceedings Against Bayer’s Patent Covering STIVARGA®, PTAB Litigation Blog
    View All

    Speaking Engagements

    • April 9, 2016
      PharmaDJ Roundtable Discussion on Biosimilar and Antibody Development: Options for Asian Biosimilar Companies in the U.S.
    • October 28, 2010
      The Advent of Biosimilars: What you (and your clients) should know
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.